Acute perfusion of BMAA in the rat's striatum by in vivo microdialysis

Toxicology Letters

Volumn 167, Issue 1, 2006, Pages 34-39

  Santiago, M ^a   Matarredona, E R ^a   Machado, A ^a   Cano, J ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

N Methylamino l alanine toxicity; Dopamine microdialysis; MPP+ challenge; Rat's striatum

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 2 AMINO 3 METHYLAMINOPROPIONIC ACID; DOPAMINE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TOXICITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DOSE RESPONSE; IMPLANTATION; MALE; MECHANICAL PROBE; MICRODIALYSIS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; TIME; TOXICITY TESTING;

3,4-DIHYDROXYPHENYLACETIC ACID; AMINO ACIDS, DIAMINO; ANIMALS; CELL DEATH; CEREBROVASCULAR CIRCULATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; ELECTROCHEMISTRY; EXCITATORY AMINO ACID AGONISTS; EXTRACELLULAR SPACE; HOMOVANILLIC ACID; MICRODIALYSIS; NEOSTRIATUM; PERFUSION; RATS; RATS, WISTAR;

EID: 33749587985     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2006.08.005     Document Type: Article

References (35)

1. Allen C.N., Omelchenko I., Ross S.M., and Spencer P. The neurotoxin, β-N-methylamino-l-alanine (BMAA) interacts with the strychnine-insensitive glycine receptors modulatory site of the N-methyl-d-aspartate receptor. Neuropharmacology 34 (1995) 651-658
2. Andrews S.H. Neurological disease on Guam: a review of past and present investigations. Bull. L.A. Neurol. Sci. 32 (1967) 30-42
3. Banack S.A., and Cox P.A. Distribution of the neurotoxic non-protein amino acid BMAA in Cycas Micronesia. Bot. J. Linnean Soc. 143 (2003) 165-168
4. Blandini F., Nappi G., Tassorelli C., and Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog. Neurobiol. 62 (2000) 63-88
5. +. Free Rad. Biol. Med. 13 (1992) 581-583
6. Cox P.A., Banack S.A., and Murch S.J. Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease aong the Chamorro people of Guam. Proc. Natl. Acad. Sci. USA 100 (2003) 13380-13383
7. Dawson Jr. R., Marschall E.G., Chan K.C., Millard W.J., Eppler B., and Patterson T.A. Neurochemical and neurobehavioral effects of neonatal administration of β-N-methylamino-l-alanine and 3.3′-iminodipropionitrile. Neurotoxicol. Teratol. 20 (1998) 181-192
8. Duncan M.W. β-Methylamino-l-alanine (BMAA) and amyotrophic lateral sclerosis-parkinsonism dementia of the western Pacific. Ann. NY Acad. Sci. 48 (1992) 161-168
9. Duncan M.W., Steele J.C., Kopin I.J., and Markey S.P. 2-Amino-3-(methylamino)propanoic acid (BMAA) in cycad flour: an unlike cause of amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. Neurology 40 (1990) 767-772
10. Giovanni A., Sieber B.-A., Heikkila R.E., and Sonsalla P.K. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: central administration of 1-methyl-4-phenylpyridinium. J. Pharmacol. Exp. Ther. 270 (1994) 1008-1014
11. Ince P.G., and Codd G.A. Return to the cycad hypothesis-does the amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC) of Guam have new implications for global health?. Neuropathol. Appl. Neurobiol. 31 (2005) 345-353
12. Kurland L.T. Amyotrphic lateral sclerosis and Parkinson's disease complex on Guam linked to an environmental toxin. Trends Neurosci. 11 (1988) 51-53
13. Kurland L.T., Radhkrishnan K., Williams D.B., and Waring S.C. Amyotrophic lateral sclerosis-parkinsonism-dementia complex: epidemiological and etiological perspectives. In: Williams A. (Ed). Motor Neuron Disease (1994), Chapman and Hall, London 109-130
14. Mitsumoto H., and Pioro E.P. Animal model of amyotrophic lateal sclerosis. In: Serratrice G., and Munset T. (Eds). Pathogenesis and Therapy of Amyotrophic Lateral Sclerosis (1995), Lippincott-Raven Pub, Philadelphia 73-87
15. Montine T.J., Li K., Perl D.P., and Galasko D. Lack of β-methylamino-l-alanine in brain from controls, AD, or Chamorros with PDC. Neurology 65 (2005) 768-769
16. Murch S.J., Cox P.A., and Banack S.A. A mechanism for slow release of biomagnified cyanobacterial neurotoxin and neurodegenerative disease in Guam. Proc. Natl. Acad. Sci. USA 101 (2004) 12228-12231
17. Murch S.J., Cox P.A., Banack S.A., Steele J.C., and Sacks O.W. Occurrence of β-methylamino-l-alanine (BMAA) in ALS/PDC patients from Guam. Acta Neurol. Scand. 110 (2004) 267-269
18. Nicklas W.J., Vyas I., and Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36 (1985) 2503-2508
19. Nunn P.B., Vega A., and Bell E.A. Neurotoxic effects of α-amino-β-methylaminopropionic acid. Biochem. J. 106 (1968) 15P
20. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press, New York
21. Polsky F.I., Nunn P.B., and Bell E.A. Distribution and toxicity of alpha-amino-beta-methylaminopropionic acid. Fed. Proc. 31 (1972) 1473-1475
22. Ramsay R.R., Dadgar J., Trevor A., and Singer T.P. Energy driven uptake of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by brain mitochondria mediates the neurotoxicity of MPTP. Life Sci. 39 (1986) 581-588
23. +. Eur. J. Pharmacol. 126 (1986) 345-346
24. +-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J. Pharmacol. Exp. Ther. 268 (1994) 380-387
25. Ross S.M., and Spencer P.S. Specific antagonism of behavioural action of "uncommon" amino acid linked to motor-system disease. Synapse 1 (1987) 248-253
26. Santiago M., Machado A., and Cano J. Validity of a quantitative technique to study dopaminergic neurodegeneration by in vivo microdialysis. J. Neurosci. Meth. 108 (2001) 181-187
27. Santiago M., and Westerink B.H.C. Characterization of the in vivo release of dopamine as recorded by different types of intracerebral microdialysis probes. Naunyn-Schmied. Arch. Pharmacol. 342 (1990) 407-414
28. Sayre L.M. Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol. Lett. 48 (1989) 121-129
29. Seawright A.A., Brown A.W., Nolan C.C., and Cavanagh J.B. Selective degeneration of cerebellar cortical neurons caused by cycas neurotoxin, l-beta-methylaminoalanine (l-BMAA) in rats. Neuropathol. Appl. Neurobiol. 16 (1990) 153-169
30. Smith S.E., and Meldrum B.S. Receptor site specificity for the acute effects of beta-N-methylamino-alanine in mice. Eur. J. Pharmacol. 187 (1990) 131-134
31. Spencer P.S., Nunn P.B., Hugon J., Ludolph A.C., Ross S.M., Roy D.N., and Robertson R.C. Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neutoxin. Science 237 (1987) 517-522
32. Spencer P.S., Kisby G.E., and Ludolph A.C. Slow toxins, biologic markers, and long-latency neurodegenerative disease in the western Pacific region. Neurology 41 (1991) 62-66
33. Vega A., Bell E.A., and Nunn P.B. The preparation of l- and d-α-amino-β-methylaminopropionic acids and theidentification fo the compound isolates form Cycas circinalis as the l-isomer. Phytochemistry 7 (1968) 1885-1887
34. Westerink B.H.C., Damsma G., Rollema H., de Vries J.B., and Horn A.S. Scope and limitations of in vivo brain dialysis: a comparison of its applications to various neurotransmitter systems. Life Sci. 41 (1987) 1763-1776
35. Wilson J.M.B., Khabazian I., Wong M.C., Seyedalikhani A., Bains J.S., Pasqualotto B.A., Williams D.E., Andersen R.J., Simpson R.J., Smith R., Craig U.-K., Kurland L.T., and Shaw C.A. Behavioral and neurological correlates of ALS-Parkinsonism dementia complex in adult mice fed washed cycad flour. Neuromol. Med. 1 (2002) 207-221